LONDON and RALEIGH, N.C., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the following conferences in March 2025:
TD Cowen 45th Annual Health Care Conference
Date: Monday, March 3, 2025
Time: 11:10 a.m. ET / 4:10 p.m. GMT
Location: Boston, MA
Leerink Partners 2025 Global Healthcare Conference
Date: Monday, March 10, 2025
Time: 8:40 a.m. ET / 1:40 p.m. GMT
Location: Miami, FL
A webcast of each conference presentation will be available on the Events and Presentations link on the Investors page of the Company’s website, www.veronapharma.com.
For further information please contact:
| Verona Pharma plc | Tel: +1-844-341-9901 |
| Victoria Stewart, Senior Director of Investor Relations and Communications | This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Argot Partners US Investor Enquiries | Tel: +1-212-600-1902 This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Ten Bridge Communications International / US Media Enquiries | Tel: +1-781-316-4424 This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Wendy Ryan |
About Verona Pharma
Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs. Ohtuvayre™ (ensifentrine) is the Company’s first commercial product and the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. Ensifentrine has potential applications in non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com.
| Last Trade: | US$81.20 |
| Daily Change: | 3.71 4.79 |
| Daily Volume: | 2,936,795 |
| Market Cap: | US$6.640B |
May 06, 2025 April 29, 2025 February 27, 2025 January 07, 2025 November 05, 2024 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
